EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 40 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR For Esophageal Cancer, Immunotherapy Likely to Play Larger Role October 19, 2020 ESMO awards its first fellowship to support digital and computational pathology September 10, 2025 Olaparib after Initial Treatment Delays Ovarian Cancer Progression November 20, 2018 GreaterGood Charities Provides Supplies and Support to People and Pets After... December 17, 2021 Load more HOT NEWS ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) 2025 ESMO Society Award recipients announced A Novel Combination of Cabozantinib Plus Atezolizumab Demonstrates Encouraging Activity and... FDA Approves Device for Treatment of Osteoid Osteoma in the Extremities
